Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ivosidenib in IDH1-mutant advanced conventional chondrosarcoma
NL-OMON60323Phase 3Not yet recruiting
- Sponsor
- Servier
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ivosidenib in chondrosarcoma (2 arms), sponsored by Servier. Primary endpoint: Progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
ivosidenib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NL-OMON60323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60323.